Denver, Colorado
,
USA
5 - 9 November 2026
American Association for the Study of Liver Diseases (AASLD 2026)
Medical Commentary: Liver Health, MASLD and MASH
In this interview, Dr. Eric Lawitz discusses liver health, MASLD and MASH, including identifying people at risk, fibrosis risk stratification and the use of non-invasive tests. He also shares his perspective on integrating liver health into cardiometabolic care and improving the evaluation and management of people with MASH.
The views and opinions expressed in this video are those of Dr. Eric Lawitz and do not necessarily reflect the official position of Novo
The views and opinions expressed in this video are those of Dr. Eric Lawitz and do not necessarily reflect the official position of Novo
Presentation schedule and materials
Friday, 06 November 2026
13:00
- 14:00
MST
POSTER
Real-world comparative effectiveness of semaglutide versus resmetirom on liver enzymes and cardiometabolic markers in patients with MASH
Prachi Arora, PhD1; David Shi, PhD, MBA1; Abdalla Aly, PhD1; Husam Albarmawi, PhD1; Maximilian Kurt Jara, MsC, MD1; Eric Lawitz, MD2
MATERIALS AVAILABLE
Coming soon
13:00
- 14:00
MST
POSTER
Semaglutide 2.4 mg and the Changes in Liver Enzymes and Cardiometabolic Markers in Patients With MASH: A Descriptive Real-World Data Study
Husam Albarmawi, PhD1; David Shi, PhD, MBA1; Abdalla Aly, PhD1; Katie Brown, PhD, MSN, RB2; Katie Gilbert, PhD2; Sunny Guin, PhD2; Ben Hong, MS2; Maximilian Kurt Jara, MSc, MD1; Amy Wu, BA2; Eric Lawitz, MD34
MATERIALS AVAILABLE
Coming soon
13:00
- 14:00
MST
POSTER
The Economic Burden of Patients with Metabolic Dysfunction Associated Steatohepatitis Stratified by Baseline and Changes in FIB-4 Index
David Shi, PhD, MBA1; Abdalla Aly, PhD1; Andres Quintero, MD, MPH, MBA1; Guanghao Zhang, PhD, MS1; Husam Albarmawi, PhD1; Hashem B. El-Serag, MD, MPH2
MATERIALS AVAILABLE
Coming soon
13:00
- 14:00
MST
POSTER
The Impact of Cardiometabolic Risk Factors on Health Care Resource Use in Adult Patients Living with Steatotic Liver Disease
Guanghao Zhang, PhD, MS1; Abdalla Aly, PhD1; Andres Quintero, MD, MPH, MBA1; David Shi, PhD, MBA1; Aidan McGovern, MPH1; Hashem B. El-Serag, MD, MPH2
MATERIALS AVAILABLE
Coming soon
13:00
- 14:00
MST
POSTER
ACT on MASH – US Data: A survey of awareness, understanding, and perceptions of MASLD and MASH among healthcare professionals
Husam Albarmawi, PhD1*; Nathalie Eklöf, MD2*;Maximilian Jara, MD1; Jeff McIntyre, MA3; Marco Antonio Petti, MD1; Lauren D. Nephew, MD, MSCE4
MATERIALS AVAILABLE
Coming soon
13:00
- 14:00
MST
POSTER
ACT on MASH – US Data: A survey of awareness, understanding, and perceptions of MASLD and MASH among people living with MASLD/MASH or at risk for MASH
Husam Albarmawi, PhD1*; Nathalie Eklöf, MD2*;Maximilian Jara, MD1; Jeff McIntyre, MA3; Marco Antonio Petti, MD1; Lauren D. Nephew, MD, MSCE4
MATERIALS AVAILABLE
Coming soon
Saturday, 07 November 2026
13:00
- 14:00
MST
POSTER
Efruxifermin improved fibrosis in participants with MASH cirrhosis and multiple cardiometabolic comorbidities: a post hoc analysis of the SYMMETRY Phase 2b trial
Mary Rinella1; Alex Liberman2; Sonja Billes2; Meena Jain2; Mazen Noureddin3
MATERIALS AVAILABLE
Coming soon
Sunday, 08 November 2026
11:00
- 11:15
MST
:0087
POSTER
Effects of zalfermin, cagrilintide, and semaglutide on non-invasive fibrosis biomarkers in alcohol-related liver disease: A phase 2 randomized trial
Vijay Shah1; Juan Pablo Arab2; Ramon Bataller3; Jerome Boursier4; Jacob George5; Lise Lotte Gluud6; Kenichi Ikejima7; Maria Rodrigo-Domingo8; Mazen Noureddin9,10; Jörn M. Schattenberg11,12; Ahsan Shoeb8,13; Irina Yoffe8; Aleksander Krag14
MATERIALS AVAILABLE
Coming soon
11:45
- 12:00
MST
:0072
POSTER
Semaglutide improves liver health in non‑obese participants with MASH: A post hoc analysis from the phase 3 ESSENCE trial
Jörn M. Schattenberg1; Matthew J. Armstrong2; Igor Bakulin3; Anja Geerts4; Jacob George5; Ewa Janczewska6; Niels Krarup7; Chun-Jen Liu8; Håvard Midgard9; Ahsan Shoeb7; Thea Vestergaard7; Michael Roden10; on behalf of the ESSENCE Study Group
MATERIALS AVAILABLE
Coming soon
12:45
- 13:30
MST
Symposium
FGF21 analogs in focus: From pathways to clinical evidence in MASH
Arun Sanyal
;
Kris Kowdley
MATERIALS AVAILABLE
Coming soon
Keywords